NASDAQ:BCAX

Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Bicara Therapeutics logo
$9.40 -0.20 (-2.07%)
As of 03:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Bicara Therapeutics Stock (NASDAQ:BCAX)

Advanced

Key Stats

Today's Range
$9.11
▼
$9.58
50-Day Range
$7.93
▼
$23.64
52-Week Range
$7.87
▼
$30.99
Volume
538,711 shs
Average Volume
771,833 shs
Market Capitalization
$624.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.33
Consensus Rating
Moderate Buy

Company Overview

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses.

The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression. The candidate is being studied in clinical trials, including in head and neck cancer.

Bicara is based in the Boston area and was established in 2018. Its chief executive officer is Christopher McNulty.

AI Generated. May Contain Errors.

Bicara Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

BCAX MarketRank™: 
3.128903654485 of 5 stars

Bicara Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 339th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bicara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.72, and is based on 2 strong buy ratings, 11 buy ratings, 3 hold ratings, and 2 sell ratings.

  • Upside Potential

    Bicara Therapeutics has a consensus price target of $30.33, representing about 223.3% upside from its current price of $9.38.

  • Amount of Analyst Coverage

    Bicara Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bicara Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bicara Therapeutics are expected to decrease in the coming year, from ($3.82) to ($4.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bicara Therapeutics is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bicara Therapeutics is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bicara Therapeutics has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    17.29% of the float of Bicara Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bicara Therapeutics has a short interest ratio ("days to cover") of 3.84, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bicara Therapeutics has recently decreased by 4.24%, indicating that investor sentiment is improving.
  • Dividend Yield

    Bicara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Bicara Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Bicara Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Bicara Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    13 people have searched for BCAX on MarketBeat in the last 30 days. This is an increase of 160% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bicara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $400,750.00 in company stock.

  • Percentage Held by Insiders

    13.80% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Bicara Therapeutics has minimal institutional ownership at this time.

  • Read more about Bicara Therapeutics' insider trading history.
Receive BCAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCAX Stock News Headlines

Research Analysts Set Expectations for BCAX FY2026 Earnings
What is HC Wainwright's Forecast for BCAX Q1 Earnings?
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Headlines

BCAX Stock Analysis - Frequently Asked Questions

Bicara Therapeutics' stock was trading at $16.83 at the start of the year. Since then, BCAX shares have decreased by 44.3% and is now trading at $9.3810.

Bicara Therapeutics Inc. (NASDAQ:BCAX) released its quarterly earnings data on Monday, November, 9th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.22.
Read the conference call transcript
.

Bicara Therapeutics (BCAX) raised $298 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 17,500,000 shares at a price of $16.00-$18.00 per share.

Top institutional shareholders of Bicara Therapeutics include State Street Corp (3.11%), Bellevue Group AG (1.09%), Nan Fung Trinity HK Ltd. (0.65%) and Goldman Sachs Group Inc. (0.61%). Insiders that own company stock include Ra Capital Management, LP, Claire Mazumdar, Ryan Cohlhepp, Ivan Hyep and David Raben.
View institutional ownership trends
.

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/09/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BCAX
Previous Symbol
NASDAQ:BCAX
CIK
2023658
Fax
N/A
Employees
103
Year Founded
2020

Price Target and Rating

High Price Target
$43.00
Low Price Target
$8.00
Potential Upside/Downside
+223.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.72
Research Coverage
18 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$137.95 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-49.13%
Return on Assets
-45.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.81
Quick Ratio
8.81

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.17 per share
Price / Book
1.52

Miscellaneous

Outstanding Shares
66,390,000
Free Float
57,226,000
Market Cap
$622.74 million
Optionable
Optionable
Beta
-0.33

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:BCAX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners